Emerging drugs for acute and chronic heart failure: current and future developments

Bibliography

• DEFRANCES CJ, PODGORNIK MN: 2004 National Hospital Discharge Survey. Advance Data (2006) (371):1-19.
   PubMedGoogle Scholar
• THOM T, HAASE N, ROSAMOND W et al.: Heart disease and stroke statistics – 2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation (2006) 113(6):e85-e151.
   PubMed Web of Science ®Google Scholar
• COHN JN: New therapeutic strategies for heart failure: left ventricular remodeling as a target. J. Card. Fail. (2004) 10(Suppl. 6):S200-S201.
   PubMed Web of Science ®Google Scholar
• GOLDSMITH SR, FRANCIS GS, COWLEY AW Jr, LEVINE TB, COHN JN: Increased plasma arginine vasopressin levels in patients with congestive heart failure. J. Am. Coll. Cardiol. (1983) 1(6):1385-1390.
   PubMed Web of Science ®Google Scholar
• NAKAMURA Y, HANEDA T, OSAKI J, MIYATA S, KIKUCHI K: Hypertrophic growth of cultured neonatal rat heart cells mediated by vasopressin V1A receptor. Eur. J. Pharmacol. (2000) 391(1-2):39-48.
   PubMed Web of Science ®Google Scholar
• CHRISTENSEN BM, MARPLES D, JENSEN UB et al.: Acute effects of vasopressin V2-receptor antagonist on kidney AQP2 expression and subcellular distribution. Am. J. Physiol. (1998) 275(2 Part 2):F285-F297.
   PubMed Web of Science ®Google Scholar
• KLEIN L, GATTIS WA, LEIMBERGER JD, PINA IL, O'CONNOR CM, GHEORGHIADE M: Prognostic value of hyponatremia in hospitalized patients with worsening heart failure – insights from the outcomes of a prospective trial of intravenous milrinone for exacerbations of chronic heart failure (OPTIME – CHF). J. Card. Fail. (2003) 9(5):S83.
   Google Scholar
• GOLDSMITH SR, FRANCIS GS, COWLEY AW Jr, GOLDENBERG IF, COHN JN: Hemodynamic effects of infused arginine vasopressin in congestive heart failure. J. Am. Coll. Cardiol. (1986) 8(4):779-783.
   PubMed Web of Science ®Google Scholar
• GHEORGHIADE M, GATTIS WA, O’CONNOR CM et al.: Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA (2004) 291(16):1963-1971.
   PubMed Web of Science ®Google Scholar
• UDELSON JE: Multicenter, randomized double-blind, placebo-controlled, efficacy study on the effects of oral tolvaptan on LV dilatation and function in patients with HF and LV systolic dysfunction. Recent and late breaking clinical trials. Program and abstracts from the 9th Annual Scientific Meeting of the Heart Failure Society of America. Boca Raton, Florida, USA, September 18 – 21 (2005).
   Google Scholar
• GHEORGHIADE M, ORLANDI C, BURNETT JC et al.: Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST). J. Card. Fail. (2005) 11(4):260-269.
   PubMed Web of Science ®Google Scholar
• UDELSON JE, SMITH WB, HENDRIX GH et al.: Acute hemodynamic effects of conivaptan, a dual V1A and V2 vasopressin receptor antagonist, in patients with advanced heart failure. Circulation (2001) 104(20):2417-2423.
   PubMed Web of Science ®Google Scholar
• GOLDSMITH SR: Efficacy and safety of conivaptan in acute decompensated heart failure: a dose-ranging pilot study. Program and abstracts from the 10th Annual Scientific Meeting of the Heart Failure Society of America, Seattle, USA, September 10 – 13 (2006) (Abstract 226).
   Google Scholar
• RUSSELL SD, SELARU P, PYNE DA et al.: Rationale for use of an exercise end point and design for the ADVANCE (A Dose evaluation of a Vasopressin ANtagonist in CHF patients undergoing Exercise) trial. Am. Heart J. (2003) 145(1):179-186.
   PubMed Web of Science ®Google Scholar
• WONG F, BLEI AT, BLENDIS LM, THULUVATH PJ: A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial. Hepatology (2003) 37(1):182-191.
   PubMed Web of Science ®Google Scholar
• ABRAHAM WT, SHAMSHIRSAZ AA, MCFANN K, OREN RM, SCHRIER RW: Aquaretic effect of lixivaptan, an oral, non-peptide, selective V2 receptor vasopressin antagonist, in New York Heart Association functional class II and III chronic heart failure patients. J. Am. Coll. Cardiol. (2006) 47(8):1615-1621.
   PubMed Web of Science ®Google Scholar
• PURSCHKE WG, EULBERG D, BUCHNER K, VONHOFF S, KLUSSMANN S: An L-RNA-based aquaretic agent that inhibits vasopressin in vivo. Proc. Natl. Acad. Sci. USA (2006) 103(13):5173-5178.
   PubMed Web of Science ®Google Scholar
• DE BOLD AJ, BORENSTEIN HB, VERESS AT, SONNENBERG H: A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci. (1981) 28(1):89-94.
   PubMed Web of Science ®Google Scholar
• MUNAGALA VK, BURNETT JC Jr, REDFIELD MM: The natriuretic peptides in cardiovascular medicine. Curr. Problems Cardiol. (2004) 29(12):707-769.
   PubMed Web of Science ®Google Scholar
• SILVER MA: The natriuretic peptide system: kidney and cardiovascular effects. Curr. Opin. Nephrol. Hypertens. (2006) 15(1):14-21.
   PubMed Web of Science ®Google Scholar
• SACKNER-BERNSTEIN JD, KOWALSKI M, FOX M, AARONSON K: Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA (2005) 293(15):1900-1905.
   PubMed Web of Science ®Google Scholar
• SACKNER-BERNSTEIN JD, SKOPICKI HA, AARONSON KD: Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation (2005) 111(12):1487-1491.
   PubMed Web of Science ®Google Scholar
• SUWA M, SEINO Y, NOMACHI Y, MATSUKI S, FUNAHASHI K: Multicenter prospective investigation on efficacy and safety of carperitide for acute heart failure in the ‘real world’ of therapy. Circ. J. (2005) 69(3):283-290.
   PubMed Web of Science ®Google Scholar
• MITROVIC V, LUSS H, NITSCHE K et al.: Effects of the renal natriuretic peptide urodilatin (ularitide) in patients with decompensated chronic heart failure: a double-blind, placebo-controlled, ascending-dose trial. Am. Heart J. (2005) 150(6):1239.
   PubMed Web of Science ®Google Scholar
• MITROVIC V, SEFEROVIC PM, SIMEUNOVIC D et al.: Haemodynamic and clinical effects of ularitide in decompensated heart failure. Eur. Heart J. (2006) 27(23):2823-2832.
   Google Scholar
• XU DL, MARTIN PY, OHARA M et al.: Upregulation of aquaporin-2 water channel expression in chronic heart failure rat. J. Clin. Investig. (1997) 99(7):1500-1505.
   PubMed Web of Science ®Google Scholar
• ELKAYAM U, MEHRA A, COHEN G et al.: Renal circulatory effects of adenosine in patients with chronic heart failure. J. Am. Coll. Cardiol. (1998) 32(1):211-215.
   PubMed Web of Science ®Google Scholar
• JACKSON EK, DUBEY RK: Role of the extracellular cAMP-adenosine pathway in renal physiology. Am. J. Physiol. Renal Physiol. (2001) 281(4):F597-F612.
   PubMed Web of Science ®Google Scholar
• GOTTLIEB SS, SKETTINO SL, WOLFF A et al.: Effects of BG-9719 (CVT-124), an A1-adenosine receptor antagonist, and furosemide on glomerular filtration rate and natriuresis in patients with congestive heart failure. J. Am. Coll. Cardiol. (2000) 35(1):56-59.
   PubMed Web of Science ®Google Scholar
• GOTTLIEB SS, BRATER DC, THOMAS I et al.: BG-9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation (2002) 105(11):1348-1353.
   PubMed Web of Science ®Google Scholar
• DITTRICH HC, TANSEY M, COTTER G et al.: Effects of the adenosine A1 receptor antagonist, KW-3902, alone and in combination with furosemide, on diuresis and renal function in hospitalized acutely decompensated heart failure patients with renal impairment: a randomized, double-blind, placebo-controlled, dose-ranging study. Program and abstracts from the 10th Annual Scientific Meeting of the Heart Failure Society of America. Washington, USA, September 10 – 13 (2006) (Abstract 224).
   Google Scholar
• COLETTA AP, TIN L, LOH PH, CLARK AL, CLELAND JG: Clinical trials update from the European Society of Cardiology heart failure meeting: TNT subgroup analysis, darbepoetin alfa, FERRIC-HF and KW-3902. Eur. J. Heart Fail. (2006) 8(5):547-549.
   PubMed Web of Science ®Google Scholar
• COOPER ME: Importance of advanced glycation end products in diabetes-associated cardiovascular and renal disease. Am. J. Hypertens. (2004) 17(12 Part 2):31S-38S.
   PubMedGoogle Scholar
• KASS DA, SHAPIRO EP, KAWAGUCHI M et al.: Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation (2001) 104(13):1464-1470.
   PubMed Web of Science ®Google Scholar
• LITTLE WC, ZILE MR, KITZMAN DW et al.: The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure. J. Card. Fail. (2005) 11(3):191-195.
   PubMed Web of Science ®Google Scholar
• LAURENT GJ: Dynamic state of collagen: pathways of collagen degradation in vivo and their possible role in regulation of collagen mass. Am. J. Physiol. (1987) 252(1 Part 1):C1-C9.
   PubMed Web of Science ®Google Scholar
• AHMED SH, CLARK LL, PENNINGTON WR et al.: Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation (2006) 113(17):2089-2096.
   PubMed Web of Science ®Google Scholar
• YARBROUGH WM, MUKHERJEE R, ESCOBAR GP et al.: Selective targeting and timing of matrix metalloproteinase inhibition in post-myocardial infarction remodeling. Circulation (2003) 108(14):1753-1759.
   PubMed Web of Science ®Google Scholar
• MORITA H, KHANAL S, RASTOGI S et al.: Selective matrix metalloproteinase inhibition attenuates progression of left ventricular dysfunction and remodeling in dogs with chronic heart failure. Am. J. Physiol. (2006) 290(6):H2522-H2527.
   Web of Science ®Google Scholar
• HUDSON MP, ARMSTRONG PW, RUZYLLO W et al.: Effects of selective matrix metalloproteinase inhibitor (PG-116800) to prevent ventricular remodeling after myocardial infarction: results of the PREMIER (Prevention of Myocardial Infarction Early Remodeling) trial. J. Am. Coll. Cardiol. (2006) 48(1):15-20.
   PubMed Web of Science ®Google Scholar
• DESCHAMPS AM, SPINALE FG: Pathways of matrix metalloproteinase induction in heart failure: bioactive molecules and transcriptional regulation. Cardiovasc. Res. (2006) 69(3):666-676.
   Google Scholar
• EATON JW, QIAN M: Interactions of copper with glycated proteins: possible involvement in the etiology of diabetic neuropathy. Mol. Cell. Biochem. (2002) 234-235(1-2):135-142.
   PubMed Web of Science ®Google Scholar
• QIAN M, LIU M, EATON JW: Transition metals bind to glycated proteins forming redox active ‘glycochelates’: implications for the pathogenesis of certain diabetic complications. Biochem. Biophys. Res. Comm. (1998) 250(2):385-389.
   PubMed Web of Science ®Google Scholar
• COOPER GJ, PHILLIPS AR, CHOONG SY et al.: Regeneration of the heart in diabetes by selective copper chelation. Diabetes (2004) 53(9):2501-2508.
   PubMed Web of Science ®Google Scholar
• COOPER GJ, YOUNG AA, GAMBLE GD et al.: Hyperglycemia-induced disorder of cardiac copper regulation is a newly-recognised mechanism of left ventricular disease in diabetes. Program and abstracts from the 10th Annual Scientific Meeting of the Heart Failure Society of America. Seattle, USA, September 10-13 (2006) (Abstract 226).
   Google Scholar
• KIVIKKO M, LEHTONEN L: Levosimendan: a new inodilatory drug for the treatment of decompensated heart failure. Curr. Pharm. Des. (2005) 11(4):435-455.
   PubMed Web of Science ®Google Scholar
• HASENFUSS G, PIESKE B, KRETSCHMANN B et al.: Effects of calcium sensitizers on intracellular calcium handling and myocardial energetics. J. Cardiovasc. Pharmacol. (1995) 26(Suppl. 1):S45-S51.
   PubMed Web of Science ®Google Scholar
• ERDEI N, PAPP Z, POLLESELLO P, EDES I, BAGI Z: The levosimendan metabolite OR-1896 elicits vasodilation by activating the K(ATP) and BK(Ca) channels in rat isolated arterioles. Br. J. Pharmacol. (2006) 148(5):696-702.
   PubMed Web of Science ®Google Scholar
• FOLLATH F, CLELAND JG, JUST H et al.: Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet (2002) 360(9328):196-202.
   PubMed Web of Science ®Google Scholar
• CLELAND JG, GHOSH J, FREEMANTLE N et al.: Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-Lipids and cardiac resynchronisation therapy in heart failure. Eur. J. Heart Fail. (2004) 6(4):501-508.
   PubMed Web of Science ®Google Scholar
• MOISEYEV VS, PODER P, ANDREJEVS N et al.: Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur. Heart J. (2002) 23(18):1422-1432.
   PubMed Web of Science ®Google Scholar
• ANTILA S, KIVIKKO M, LEHTONEN L et al.: Pharmacokinetics of levosimendan and its circulating metabolites in patients with heart failure after an extended continuous infusion of levosimendan. Br. J. Clin. Pharmacol. (2004) 57(4):412-415.
   PubMed Web of Science ®Google Scholar
• KIVIKKO M, LEHTONEN L, COLUCCI WS: Sustained hemodynamic effects of intravenous levosimendan. Circulation (2003) 107(1):81-86.
   PubMed Web of Science ®Google Scholar
• FOLLATH F, FRANCO F, CARDOSO JS: European experience on the practical use of levosimendan in patients with acute heart failure syndromes. Am. J. Cardiol. (2005) 96(6A):80G-85G.
   PubMed Web of Science ®Google Scholar
• CLELAND JG, FREEMANTLE N, COLETTA AP, CLARK AL: Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE. Eur. J. Heart Fail. (2006) 8(1):105-110.
   PubMed Web of Science ®Google Scholar
• MALIK F, ELIAS KA, FINER JT et al.: Direct activation of cardiac myosin by CK-1827452 improves cardiac function in a dog heart failure model. Heart Failure Society of America Meeting, Florida, USA (2005) (Poster 017) (Poster Presentation).
   Google Scholar
• MALIK F, SHEN Y, KATORI T et al.: Direct activation of cardiac myosin, a novel mechanism for improving cardiac function. American Heart Association Keystone, Boca Raton, USA (2005) (Poster 136) (Poster Presentation).
   Google Scholar
• NIU C, ANDERSON RL, COX DR et al.: The cardiac myosin activator, CK-1122534, increases contractility in adult cardiac myocytes but does not affect the transient or depend on second messenger signaling. American Heart Association, New Orleans, USA (2004) (Poster 1500) (Poster Presentation).
   Google Scholar
• RODRIGUEZ HM, SYLVESTER S, KAWAS R, MALIK F, SAKOWICZ R: Activation of the Cardiac Sarcomere by a Small Molecule Agent, CK-1213296. Biophysical Society Annual Meeting, Salt Lake City, USA (2006) (Poster Presentation).
   Google Scholar
• BERS DM: Cardiac excitation– contraction coupling. Nature (2002) 415(6868):198-205.
   PubMed Web of Science ®Google Scholar
• ZARAIN-HERZBERG A: Regulation of the sarcoplasmic reticulum Ca2+-ATPase expression in the hypertrophic and failing heart. Canadian J. Physiol. Pharmacol. (2006) 84(5):509-521.
   PubMed Web of Science ®Google Scholar
• DHALLA NS, GOLFMAN L, LIU X et al.: Subcellular remodeling and heart dysfunction in cardiac hypertrophy due to pressure overload. Ann. NY Acad. Sci. (1999) 874:100-110.
   PubMed Web of Science ®Google Scholar
• TAKIZAWA T, ARAI M, YOGUCHI A et al.: Transcription of the SERCA2 gene is decreased in pressure-overloaded hearts: a study using in vivo direct gene transfer into living myocardium. J. Mol. Cell. Cardiol. (1999) 31(12):2167-2174.
   PubMed Web of Science ®Google Scholar
• SUAREZ J, BELKE DD, GLOSS B et al.: In vivo adenoviral transfer of sorcin reverses cardiac contractile abnormalities of diabetic cardiomyopathy. Am. J. Physiol. (2004) 286(1):H68-H75.
   Web of Science ®Google Scholar
• KOITABASHI N, ARAI M, TOMARU K et al.: Carvedilol effectively blocks oxidative stress-mediated downregulation of sarcoplasmic reticulum Ca2+-ATPase 2 gene transcription through modification of Sp1 binding. Biochem. Biophys. Res. Comm. (2005) 328(1):116-124.
   PubMed Web of Science ®Google Scholar
• MORISCOT AS, SAYEN MR, HARTONG R, WU P, DILLMANN WH: Transcription of the rat sarcoplasmic reticulum Ca2+ adenosine triphosphatase gene is increased by 3,5,3′-triiodothyronine receptor isoform-specific interactions with the myocyte-specific enhancer factor-2a. Endocrinology (1997) 138(1):26-32.
   PubMed Web of Science ®Google Scholar
• KLEIN I, OJAMAA K: Thyroid hormone and the cardiovascular system. N. Engl. J. Med. (2001) 344(7):501-509.
   PubMed Web of Science ®Google Scholar
• SPOONER PH, MORKIN E, GOLDMAN S: Thyroid hormone and thyroid hormone analogues in the treatment of heart failure. Coronary Artery Dis. (1999) 10(6):395-399.
   PubMed Web of Science ®Google Scholar
• HAMILTON MA, STEVENSON LW, LUU M, WALDEN JA: Altered thyroid hormone metabolism in advanced heart failure. J. Am. Coll. Cardiol. (1990) 16(1):91-95.
   PubMed Web of Science ®Google Scholar
• HAMILTON MA, STEVENSON LW, FONAROW GC et al.: Safety and hemodynamic effects of intravenous triiodothyronine in advanced congestive heart failure. Am. J. Cardiol. (1998) 81(4):443-447.
   PubMed Web of Science ®Google Scholar
• MORKIN E, PENNOCK G, SPOONER PH et al.: Pilot studies on the use of 3,5-diiodothyropropionic acid, a thyroid hormone analog, in the treatment of congestive heart failure. Cardiology (2002) 97(4):218-225.
   PubMed Web of Science ®Google Scholar
• FAZIO S, CITTADINI A, SABATINI D et al.: Growth hormone and heart performance. A novel mechanism of cardiac wall stress regulation in humans. Eur. Heart J. (1997) 18(2):340-347.
   PubMed Web of Science ®Google Scholar
• FAZIO S, SABATINI D, CAPALDO B et al.: A preliminary study of growth hormone in the treatment of dilated cardiomyopathy. N. Engl. J. Med. (1996) 334(13):809-814.
   PubMed Web of Science ®Google Scholar
• OSTERZIEL KJ, STROHM O, SCHULER J et al.: Randomised, double-blind, placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy. Lancet (1998) 351(9111):1233-1237.
   PubMed Web of Science ®Google Scholar
• NAGAYA N, KANGAWA K: Ghrelin improves left ventricular dysfunction and cardiac cachexia in heart failure. Curr. Opin. Pharmacol. (2003) 3(2):146-151.
   PubMed Web of Science ®Google Scholar
• NAGAYA N, UEMATSU M, KOJIMA M et al.: Chronic administration of ghrelin improves left ventricular dysfunction and attenuates development of cardiac cachexia in rats with heart failure. Circulation (2001) 104(12):1430-1435.
   PubMed Web of Science ®Google Scholar
• BALDANZI G, FILIGHEDDU N, CUTRUPI S et al.: Ghrelin and des-acyl ghrelin inhibit cell death in cardiomyocytes and endothelial cells through ERK1/2 and PI 3-kinase/AKT. J. Cell Biol. (2002) 159(6):1029-1037.
   PubMed Web of Science ®Google Scholar
• GOLDBERG N, LUNDIN AP, DELANO B, FRIEDMAN EA, STEIN RA: Changes in left ventricular size, wall thickness, and function in anemic patients treated with recombinant human erythropoietin. Am. Heart J. (1992) 124(2):424-427.
   PubMed Web of Science ®Google Scholar
• LEVIN A: Anemia and left ventricular hypertrophy in chronic kidney disease populations: a review of the current state of knowledge. Kidney Int. (2002) 80:35-38.
   Google Scholar
• HAYASHI T, SUZUKI A, SHOJI T et al.: Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure. Am. J. Kidney Dis. (2000) 35(2):250-256.
   PubMed Web of Science ®Google Scholar
• DONNE RL, FOLEY RN: Anaemia management and cardiomyopathy in renal failure. Nephrol. Dial. Transplant. (2002) 17(Suppl. 1):37-40.
   PubMed Web of Science ®Google Scholar
• HORWICH TB, FONAROW GC, HAMILTON MA, MACLELLAN WR, BORENSTEIN J: Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. J. Am. Coll. Cardiol. (2002) 39(11):1780-1786.
   PubMed Web of Science ®Google Scholar
• SILVERBERG DS, WEXLER D, SHEPS D et al.: The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J. Am. Coll. Cardiol. (2001) 37(7):1775-1780.
   PubMed Web of Science ®Google Scholar
• SILVERBERG DS, WEXLER D, BLUM M et al.: The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J. Am. Coll. Cardiol. (2000) 35(7):1737-1744.
   PubMed Web of Science ®Google Scholar
• EZEKOWITZ JA, MCALISTER FA, ARMSTRONG PW: Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12 065 patients with new-onset heart failure. Circulation (2003) 107(2):223-225.
   PubMed Web of Science ®Google Scholar
• MOZAFFARIAN D, NYE R, LEVY WC: Anemia predicts mortality in severe heart failure: the prospective randomized amlodipine survival evaluation (PRAISE). J. Am. Coll. Cardiol. (2003) 41(11):1933-1939.
   PubMed Web of Science ®Google Scholar
• SILVERBERG DS, WEXLER D, IAINA A: The importance of anemia and its correction in the management of severe congestive heart failure. Eur. J. Heart Fail. (2002) 4(6):681-686.
   PubMed Web of Science ®Google Scholar
• LINDENFELD J: Prevalence of anemia and effects on mortality in patients with heart failure. Am. Heart J. (2005) 149(3):391-401.
   PubMed Web of Science ®Google Scholar
• SILVERBERG DS, WEXLER D, BLUM M et al.: The effect of correction of anaemia in diabetics and non-diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron. Nephrol. Dial. Transplant. (2003) 18(1):141-146.
   PubMed Web of Science ®Google Scholar
• MANCINI DM, KATZ SD, LANG CC et al.: Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation (2003) 107(2):294-299.
   PubMed Web of Science ®Google Scholar
• CLELAND JG, COLETTA AP, NIKITIN NP, CLARK AL: Clinical trials update from the American College of Cardiology: darbepoetin alfa, ASTEROID, UNIVERSE, paediatric carvedilol, UNLOAD and ICELAND. Eur. J. Heart Fail. (2006) 8(3):326-329.
   PubMed Web of Science ®Google Scholar
• MIX TC, BRENNER RM, COOPER ME et al.: Rationale – Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease. Am. Heart J. (2005) 149(3):408-413.
   PubMed Web of Science ®Google Scholar
• KATZ SD, MANCINI D, ANDRONE AS, HRYNIEWICZ K: Treatment of anemia in patients with chronic heart failure. J. Card. Fail. (2004) 10(Suppl. 1):S13-S16.
   PubMed Web of Science ®Google Scholar
• DEPRE C, SHIPLEY GL, CHEN W et al.: Unloaded heart in vivo replicates fetal gene expression of cardiac hypertrophy. Nat. Med. (1998) 4(11):1269-1275.
   PubMed Web of Science ®Google Scholar
• GOODWIN GW, TAYLOR CS, TAEGTMEYER H: Regulation of energy metabolism of the heart during acute increase in heart work. J. Biol. Chem. (1998) 273(45):29530-29539.
   PubMed Web of Science ®Google Scholar
• YOUNG ME, LAWS FA, GOODWIN GW, TAEGTMEYER H: Reactivation of peroxisome proliferator-activated receptor α is associated with contractile dysfunction in hypertrophied rat heart. J. Biol. Chem. (2001) 276(48):44390-44395.
   PubMed Web of Science ®Google Scholar
• OLIVER MF, OPIE LH: Effects of glucose and fatty acids on myocardial ischaemia and arrhythmias. Lancet (1994) 343(8890):155-158.
   PubMed Web of Science ®Google Scholar
• ESSOP MF, OPIE LH: Metabolic therapy for heart failure. Eur. Heart J. (2004) 25(20):1765-1768.
   PubMed Web of Science ®Google Scholar
• DI NAPOLI P, TACCARDI AA, BARSOTTI A: Long term cardioprotective action of trimetazidine and potential effect on the inflammatory process in patients with ischaemic dilated cardiomyopathy. Heart (2005) 91(2):161-165.
   PubMed Web of Science ®Google Scholar
• EL-KADY T, EL-SABBAN K, GABALY M, SABRY A, ABDEL-HADY S: Effects of trimetazidine on myocardial perfusion and the contractile response of chronically dysfunctional myocardium in ischemic cardiomyopathy: a 24-month study. Am. J. Cardiovasc. Drugs (2005) 5(4):271-278.
   PubMedGoogle Scholar
• KORANTZOPOULOS P, KOUNTOURIS E, SIOGAS K, GALARIS D: The potential benefits of trimetazidine in patients with diabetes and ischemic cardiomyopathy. Am. Heart J. (2004) 148(6):e31; author reply e32.
   PubMedGoogle Scholar
• VITALE C, WAJNGATEN M, SPOSATO B et al.: Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease. Eur. Heart J. (2004) 25(20):1814-1821.
   PubMed Web of Science ®Google Scholar
• ROSANO GM, VITALE C, SPOSATO B, MERCURO G, FINI M: Trimetazidine improves left ventricular function in diabetic patients with coronary artery disease: a double-blind placebo-controlled study. Cardiovasc. Diabetol. (2003) 2:16.
   PubMed Web of Science ®Google Scholar
• FRAGASSO G, PERSEGHIN G, DE COBELLI F et al.: Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine/adenosine triphosphate ratio in patients with heart failure. Eur. Heart J. (2006) 27(8):942-948.
   PubMed Web of Science ®Google Scholar
• FRAGASSO G, PIATTI MD PM, MONTI L et al.: Short- and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy. Am. Heart J. (2003) 146(5):E18.
   PubMedGoogle Scholar
• FRAGASSO G, PALLOSHI A, PUCCETTI P et al.: A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibotir, in patients with heart failure. J. Am. Coll. Cardiol. (2006) 48(5):992-998.
   PubMed Web of Science ®Google Scholar
• ZARAIN-HERZBERG A, RUPP H, ELIMBAN V, DHALLA NS: Modification of sarcoplasmic reticulum gene expression in pressure overload cardiac hypertrophy by etomoxir. FASEB J. (1996) 10(11):1303-1309.
   PubMed Web of Science ®Google Scholar
• SCHMIDT-SCHWEDA S, HOLUBARSCH C: First clinical trial with etomoxir in patients with chronic congestive heart failure. Clin. Sci. (Lond.) (2000) 99(1):27-35.
   PubMed Web of Science ®Google Scholar
• BELARDINELLI L, SHRYOCK JC, FRASER H: Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine. Heart (2006) 92(Suppl. 4):iv6-iv14.
   PubMed Web of Science ®Google Scholar
• SABBAH HN, CHANDLER MP, MISHIMA T et al.: Ranolazine, a partial fatty acid oxidation (pFOX) inhibitor, improves left ventricular function in dogs with chronic heart failure. J. Card. Fail. (2002) 8(6):416-422.
   PubMed Web of Science ®Google Scholar
• CHANDLER MP, STANLEY WC, MORITA H et al.: Short-term treatment with ranolazine improves mechanical efficiency in dogs with chronic heart failure. Circ. Res. (2002) 91(4):278-280.
   PubMed Web of Science ®Google Scholar
• UNDROVINAS AI, BELARDINELLI L, UNDROVINAS NA, SABBAH HN: Ranolazine improves abnormal repolarization and contraction in left ventricular myocytes of dogs with heart failure by inhibiting late sodium current. J. Cardiovasc. Electrophysiol. (2006) 17(Suppl. 1):S169-S177.
   PubMedGoogle Scholar
• HAYASHIDA W, VAN EYLL C, ROUSSEAU MF, POULEUR H: Effects of ranolazine on left ventricular regional diastolic function in patients with ischemic heart disease. Cardiovasc. Drugs Ther. (1994) 8(5):741-747.
   PubMed Web of Science ®Google Scholar
• SHAH A, SHANNON RP: Insulin resistance in dilated cardiomyopathy. Rev. Cardiovasc. Med. (2003) 4(Suppl. 6):S50-S57.
   PubMedGoogle Scholar
• NIKOLAIDIS LA, STURZU A, STOLARSKI C et al.: The development of myocardial insulin resistance in conscious dogs with advanced dilated cardiomyopathy. Cardiovasc. Res. (2004) 61(2):297-306.
   PubMed Web of Science ®Google Scholar
• EGAN JM, MENEILLY GS, HABENER JF, ELAHI D: Glucagon-like peptide-1 augments insulin-mediated glucose uptake in the obese state. J. Clin. Endocrin. Metab. (2002) 87(8):3768-3773.
   PubMed Web of Science ®Google Scholar
• MENEILLY GS, MCINTOSH CH, PEDERSON RA et al.: Glucagon-like peptide-1 (7-37) augments insulin-mediated glucose uptake in elderly patients with diabetes. J. Gerontol. (2001) 56(11):M681-M685.
   Google Scholar
• NIKOLAIDIS LA, MANKAD S, SOKOS GG et al.: Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation (2004) 109(8):962-965.
   PubMed Web of Science ®Google Scholar
• NYSTROM T, GUTNIAK MK, ZHANG Q et al.: Effects of glucagon-like peptide-1 on endothelial function in Type 2 diabetes patients with stable coronary artery disease. Am. J. Physiol. Endocrinol. Metab. (2004) 287(6):E1209-E1215.
   PubMed Web of Science ®Google Scholar
• THRAINSDOTTIR I, MALMBERG K, OLSSON A, GUTNIAK M, RYDEN L: Initial experience with GLP-1 treatment on metabolic control and myocardial function in patients with Type 2 diabetes mellitus and heart failure. Diab. Vasc. Dis. Res. (2004) 1(1):40-43.
   PubMedGoogle Scholar
• SHINBANE JS, WOOD MA, JENSEN DN et al.: Tachycardia-induced cardiomyopathy: a review of animal models and clinical studies. J. Am. Coll. Cardiol. (1997) 29(4):709-715.
   PubMed Web of Science ®Google Scholar
• LECHAT P, HULOT JS, ESCOLANO S et al.: Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II trial. Circulation (2001) 103(10):1428-1433.
   PubMed Web of Science ®Google Scholar
• DIFRANCESCO D: Serious workings of the funny current. Prog. Biophys. Mol. Biol. (2006) 90(1-3):13-25.
   PubMed Web of Science ®Google Scholar
• MULDER P, BARBIER S, CHAGRAOUI A et al.: Long-term heart rate reduction induced by the selective If current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure. Circulation (2004) 109(13):1674-1679.
   PubMed Web of Science ®Google Scholar
• DE FERRARI GM, MAZZUERO A, AGNESINA L et al.: Ivabradine infusion in patients with severe heart failure is safe, reduces heart rate and increases left ventricular stroke volume and systolic work. World Congress 2006 of Cardiology Scientific Meeting, Barcelona, Spain (2006) (Poster 2100).
   Google Scholar
• STANTON A: Potential of renin inhibition in cardiovascular disease. J. Renin Angiotensin Aldosterone Syst. (2003) 4(1):6-10.
   PubMed Web of Science ®Google Scholar
• NUSSBERGER J, WUERZNER G, JENSEN C, BRUNNER HR: Angiotensin II suppression in humans by the orally active renin inhibitor aliskiren (SPP100): comparison with enalapril. Hypertension (2002) 39(1):E1-E8.
   PubMed Web of Science ®Google Scholar
• GRADMAN AH, SCHMIEDER RE, LINS RL et al.: Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation (2005) 111(8):1012-1018.
   PubMed Web of Science ®Google Scholar
• CANNON CP, BRAUNWALD E, MCCABE CH et al.: Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N. Engl. J. Med. (2004) 350(15):1495-1504.
   PubMed Web of Science ®Google Scholar
• RAUCHHAUS M, COATS AJ, ANKER SD: The endotoxin–lipoprotein hypothesis. Lancet (2000) 356(9233):930-933.
   PubMed Web of Science ®Google Scholar
• HORWICH TB, HAMILTON MA, MACLELLAN WR, FONAROW GC: Low serum total cholesterol is associated with marked increase in mortality in advanced heart failure. J. Card. Fail. (2002) 8(4):216-224.
   PubMed Web of Science ®Google Scholar
• RAUCHHAUS M, CLARK AL, DOEHNER W et al.: The relationship between cholesterol and survival in patients with chronic heart failure. J. Am. Coll. Cardiol. (2003) 42(11):1933-1940.
   PubMed Web of Science ®Google Scholar
• MARZ W, SIEKMEIER R, MULLER HM et al.: Effects of lovastatin and pravastatin on the survival of hamsters with inherited cardiomyopathy. J. Cardiovasc. Pharmacol. Ther. (2000) 5(4):275-279.
   PubMedGoogle Scholar
• LAUFS U, CUSTODIS F, BOHM M: HMG-CoA reductase inhibitors in chronic heart failure: potential mechanisms of benefit and risk. Drugs (2006) 66(2):145-154.
   PubMed Web of Science ®Google Scholar
• HORWICH TB, MACLELLAN WR, FONAROW GC: Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure. J. Am. Coll. Cardiol. (2004) 43(4):642-648.
   PubMed Web of Science ®Google Scholar
• MOZAFFARIAN D, NYE R, LEVY WC: Statin therapy is associated with lower mortality among patients with severe heart failure. Am. J. Cardiol. (2004) 93(9):1124-1129.
   PubMed Web of Science ®Google Scholar
• KJEKSHUS J, PEDERSEN TR, OLSSON AG, FAERGEMAN O, PYORALA K: The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. J. Card. Fail. (1997) 3(4):249-254.
   PubMedGoogle Scholar
• NODE K, FUJITA M, KITAKAZE M, HORI M, LIAO JK: Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation (2003) 108(7):839-843.
   PubMed Web of Science ®Google Scholar
• ANKER SD, CLARK AL, WINKLER R et al.: Statin use and survival in patients with chronic heart failure – results from two observational studies with 5200 patients. Int. J. Cardiol. (2006) 112(2):234-242.
   PubMed Web of Science ®Google Scholar
• FUKUTA H, SANE DC, BRUCKS S, LITTLE WC: Statin therapy may be associated with lower mortality in patients with diastolic heart failure: a preliminary report. Circulation (2005) 112(3):357-363.
   PubMed Web of Science ®Google Scholar
• SOLA S, MIR MQ, LERAKIS S, TANDON N, KHAN BV: Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. J. Am. Coll. Cardiol. (2006) 47(2):332-337.
   PubMed Web of Science ®Google Scholar
• KJEKSHUS J, DUNSELMAN P, BLIDESKOG M et al.: A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): study design and baseline characteristics. Eur. J. Heart Fail. (2005) 7(6):1059-1069.
   PubMed Web of Science ®Google Scholar
• TAVAZZI L, TOGNONI G, FRANZOSI MG et al.: Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure. Eur. J. Heart Fail. (2004) 6(5):635-641.
   PubMed Web of Science ®Google Scholar